★ Daily Intelligence Briefings (DIBs)⦁ Theme TrackerBiotechnology & HealthcareⓁ PharmaceuticalsMarkets Pfizer and Moderna Look to Put COVID Bust Behind Them, Add New Drug Development to Pipelines Several drugmakers whose sales boomed on COVID-19 vaccines and related products in 2021 and 2022 have now been embroiled in a hangover…McAlinden Research PartnersOctober 18, 2023
★ Daily Intelligence Briefings (DIBs)Biotechnology & HealthcareTechnology Robotic Surgical Procedures on the Rise as MedTech Firms Raise New Funds and Seek New FDA Approvals A new fundraising round by the UK's CMR Surgical, valuing the company at $3 billion, has foisted focus back onto…McAlinden Research PartnersSeptember 20, 2023
★ Daily Intelligence Briefings (DIBs)⦁ Theme TrackerBiotechnology & HealthcareⓁ PharmaceuticalsMarkets FTC Settles Suit Over Amgen-Horizon Deal, Potentially Averting Further Pharma M&A Hurdles The FTC's settlement with Amgen and Horizon has cleared the way for the two companies to complete a $27.8 billion…McAlinden Research PartnersSeptember 5, 2023
★ Daily Intelligence Briefings (DIBs)Biotechnology & HealthcareEconomics & Trade China Looks to Recharge Foreign Investment with Focus on Burgeoning Biopharma Business Some gauges indicate that foreign investment in China has sunken to 25-year lows recently. Beijing sees development of the country's biotechnology…McAlinden Research PartnersAugust 15, 2023
★ Daily Intelligence Briefings (DIBs)⦁ Theme TrackerBiotechnology & HealthcareⓁ PharmaceuticalsManufacturing & LogisticsMarkets Obesity Drugs’ Popularity Promises to Inject New Life Into Pharma Pipelines Summary: Ongoing shortages of popular obesity-fighting drugs from Novo Nordisk represent the surging popularity of medication-based intervention as treatment. Though…McAlinden Research PartnersJuly 25, 2023
★ Daily Intelligence Briefings (DIBs)Biotechnology & HealthcareMarketsPolitics & Policy Psychedelics Break New Ground in Clinical Trials, Research to be Bolstered by Key FDA Guidance New FDA guidance meant to steer clinical trials of psychedelic compounds will play a major role in the eventual approval…McAlinden Research PartnersJuly 12, 2023
★ Daily Intelligence Briefings (DIBs)⦁ Theme TrackerBiotechnology & HealthcareⓁ PharmaceuticalsMarkets Johnson & Johnson Faces Patent Hurdles in Drug Business, Potentially Setting the Tone for Pharma Peers Johnson & Johnson's most recent earnings data showed revenues and earnings per share growing more robustly than analysts anticipated. However,…McAlinden Research PartnersApril 18, 2023
★ Daily Intelligence Briefings (DIBs)⦁ Theme TrackerBiotechnology & HealthcareⓁ PharmaceuticalsMarkets Potential Pfizer-Seagen Tie Up Could Mark Largest Deal in Years, Continue to Propel Biopharma M&A Trend A potential acquisition of Seagen by Pfizer, likely in the neighborhood of $40.0 billion, would be the biggest biopharma deal…McAlinden Research PartnersFebruary 27, 2023
★ Daily Intelligence Briefings (DIBs)Biotechnology & HealthcarePolitics & Policy Psychedelics Continue to Secure Legislative Backing Across the North American Continent Throughout the past month, legislators in nearly half a dozen US states have introduced bills focused on reforming laws that…McAlinden Research PartnersJanuary 30, 2023
★ Daily Intelligence Briefings (DIBs)⦁ Theme TrackerBiotechnology & HealthcareⓁ Gene Editing FDA Approvals for Genetic Medicines Speed Ahead Despite Recent Setbacks in Base Editing Shares of biotechnology firms focused on gene editing were slammed this week by an FDA hold placed on Verve Therapeutics'…McAlinden Research PartnersDecember 8, 2022